Novo Nordisk A/S (NOVOB) recalled batches of its NovoMix 30 FlexPen and Penfill insulin after Europe’s drug regulator recommended patients not use the products to avoid dose variations. The world’s biggest insulin maker told the European Medicines Agency that a manufacturing defect caused some batches to contain 50 percent to 150 percent of the labeled amount of insulin. The Bagsvaerd, Denmark-based company couldn’t say which ones had incorrect dosages, Novo spokesman Mike Rulis said.
Help employers find you! Check out all the jobs and post your resume.
